Skip to main content
Premium Trial:

Request an Annual Quote

Millennium Extends Three Partnerships with Pharmas

Premium

CAMBRIDGE, Mass.--Millennium Pharmaceuticals announced that three of its partners have extended their strategic alliances with the company. Millennium's four-year collaboration with Pfizer, which was due to expire in December 1998, was expanded and extended for an additional two years, while a partnership with Astra will be extended for four more years. In the field of oncology, Millennium's partnership with Eli Lilly will continue an additional two years. No financial terms were disclosed.

The alliance with Pfizer, which Millennium gained through its acquisition of ChemGenics in 1997, is focused on discovery of drug leads for treating fungal infections in humans. The four-year relationship has yielded a number of targets that have advanced into drug discovery, Millennium said. As part of the two-year extension, the relationship has been expanded to create a "lead-to-target" drug discovery paradigm that expedites the identification of drug leads.

The Astra collaboration began in December 1995 and focuses on drug discovery for inflammatory respiratory diseases, including asthma, allergic rhinitis, bronchitis, emphysema, and other chronic obstructive pulmonary diseases. The four-year extension is based, in part, on Millennium's successful delivery of novel respiratory inflammation drug targets to Astra and the development of Astra's target pipeline during the alliance's first phase. Efforts of the alliance during the extension will focus on moving the targets toward drug discovery and the continued discovery and validation of new targets.

In April 1996 Millennium and Lilly entered into a strategic partnership in select areas within oncology. Lilly signed an early extension of the relationship for two more years, taking it through March 2001.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.